Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
PSMA-PET in Prostate Cancer: Evidence and Practice
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad R. Ritch, MD, MBA, FACS, discusses the practical considerations influencing PSMA-PET agent selection in prostate cancer care.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
3
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
4
SureCore needle: Interim data show longer, less fragmented cores
5